<SEC-DOCUMENT>0001104659-25-102345.txt : 20251027
<SEC-HEADER>0001104659-25-102345.hdr.sgml : 20251027
<ACCEPTANCE-DATETIME>20251027083545
ACCESSION NUMBER:		0001104659-25-102345
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20251024
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251027
DATE AS OF CHANGE:		20251027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		251417619

	BUSINESS ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		6462005278

	MAIL ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2529505d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:sls="http://sellaslifesciences.com/20251024">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_sls_sellaslifesciences.com_20251024 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20251024_20251024 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001390478 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000004" name="dei:EntityCentralIndexKey">0001390478</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="sls-20251024.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-10-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-24</xbrli:startDate>
        <xbrli:endDate>2025-10-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED STATES</b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>WASHINGTON, D.C. 20549 </b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90C_edei--DocumentType_c20251024__20251024_z5LnFl8JKcol"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PURSUANT TO SECTION 13 OR 15(d) OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event
reported): <b><span id="xdx_904_edei--DocumentPeriodEndDate_c20251024__20251024_zMm9oHhxXccg"><ix:nonNumeric contextRef="AsOf2025-10-24" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">October 24, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_900_edei--EntityRegistrantName_c20251024__20251024_zkKVysfw9Fof"><b><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000011" name="dei:EntityRegistrantName">SELLAS
Life Sciences Group, Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20251024__20251024_z9bOvHw1Fl61"><ix:nonNumeric contextRef="AsOf2025-10-24" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityFileNumber_c20251024__20251024_zn9idoxdW666"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000013" name="dei:EntityFileNumber">001-33958</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20251024__20251024_zlUmgiLeZuV6"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000014" name="dei:EntityTaxIdentificationNumber">20-8099512</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of<br/> incorporation or organization)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; padding-right: 2.65pt; padding-left: 2.65pt">(Commission <br/>
File Number)</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; padding-right: 2.65pt; padding-left: 2.65pt">(I.R.S. Employer <br/>
Identification No.)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; padding-right: 2.65pt; padding-left: 2.65pt"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20251024__20251024_zJnq8Gg0ju81"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000015" name="dei:EntityAddressAddressLine1">7 Times Square</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20251024__20251024_zT5ff6qSNOvj"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 2503</ix:nonNumeric></span><br/> </b> <b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20251024__20251024_zelDA0TcqPJi"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000017" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20251024__20251024_zzIj70lMJo2c"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000018" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20251024__20251024_zP8kJ9YC5Oud"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000019" name="dei:EntityAddressPostalZipCode">10036</ix:nonNumeric></span></b></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt">(Address of Principal Executive <br/> Offices) (Zip Code)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="5" style="padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt">Registrant&#8217;s
    telephone number, including area code: <b>(<span id="xdx_900_edei--CityAreaCode_c20251024__20251024_zq7BqQKurA41"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000020" name="dei:CityAreaCode">646</ix:nonNumeric></span>) <span id="xdx_902_edei--LocalPhoneNumber_c20251024__20251024_zzurj5hxz567"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000021" name="dei:LocalPhoneNumber">200-5278</ix:nonNumeric></span></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_902_edei--WrittenCommunications_c20251024__20251024_z7i3owEs9d33" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-10-24" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span><span style="font-size: 10pt">
Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR&#160;230.425)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90A_edei--SolicitingMaterial_c20251024__20251024_zMk8SxlKOoWi" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-10-24" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span><span style="font-size: 10pt">
Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR&#160;240.14a-12)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_904_edei--PreCommencementTenderOffer_c20251024__20251024_z9dMtaZQ8nsk" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-10-24" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span><span style="font-size: 10pt">
Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR&#160;240.14d-2(b))</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20251024__20251024_zbL1n08tnle4"><ix:nonNumeric contextRef="AsOf2025-10-24" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span> <span style="font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR&#160;240.13e-4(c))</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; width: 44%; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; width: 16%; text-align: center"><span style="font-size: 10pt"><b>Trading<br/>
    symbol(s)</b></span></td>
    <td style="border: black 1pt solid; padding: 1.5pt; width: 40%; text-align: center"><span style="font-size: 10pt"><b>Name of each
    exchange on which<br/>
    registered</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20251024__20251024_zSVTd1JoULWd"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000026" name="dei:Security12bTitle">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></span></td>
    <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--TradingSymbol_c20251024__20251024_zq9HSHQl7lT9"><ix:nonNumeric contextRef="AsOf2025-10-24" id="Fact000027" name="dei:TradingSymbol">SLS</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--SecurityExchangeName_c20251024__20251024_z2Ge9RMNBWFb"><ix:nonNumeric contextRef="AsOf2025-10-24" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Emerging growth company <span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20251024__20251024_zIFMh7bYxD83"><ix:nonNumeric contextRef="AsOf2025-10-24" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&#160;24, 2025, SELLAS Life Sciences Group,&#160;Inc. a Delaware
corporation (the &#8220;Company&#8221;), entered into a Warrant Inducement Agreement (the &#8220;Inducement Agreement&#8221;) with holders
(the &#8220;Holders&#8221;) of certain existing warrants (the &#8220;Existing Warrants&#8221;) to purchase shares of common stock, par
value $0.0001 per share (the &#8220;Common Stock&#8221;), of the Company. Pursuant to the Inducement Agreement, the Holders and the Company
agreed that, subject to any applicable beneficial ownership limitations, that the Holders would cash exercise (i)&#160;warrants to purchase
up to 6,514,658 shares of our Common Stock at an exercise price per share of $1.535, previously issued in March 2024 (the &#8220;March&#160;Warrants&#8221;),
and (ii)&#160;warrants to purchase up to 15,849,056 shares of Common Stock at an exercise price per share of $1.325, previously issued
in August 2024 (the &#8220;August&#160;Warrants,&#8221; and together with the March&#160;Warrants, the &#8220;Existing Warrants&#8221;).
The Existing Warrants were exercised at their original issuance exercise price plus $0.125 per share of Common Stock in accordance with
the rules&#160;and regulations of The Nasdaq Capital Market. The Company will receive aggregate gross proceeds of approximately $31.0
million from the exercise of the Existing Warrants before deducting financial advisory fees and other expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration of the Holders&#8217; agreement to exercise the Existing
Warrants in accordance with the Inducement Agreement, the Company agreed to issue to the Holders new warrants (the &#8220;Inducement Warrants&#8221;)
to purchase up to 22,363,714 shares of Common Stock, which is equal to 100% of the number of shares of Common Stock issued upon exercise
of the Existing Warrants (the &#8220;Inducement Warrant Shares&#8221;). The Inducement Warrants are being offered pursuant to a prospectus
supplement, dated October&#160;24, 2025 (the &#8220;Prospectus Supplement&#8221;), filed with the U.S. Securities and Exchange Commission
(the &#8220;SEC&#8221;), and an accompanying base prospectus that forms a part of the Company&#8217;s Registration Statement on Form&#160;S-3
(File No.&#160;333-278334), which was previously filed with the SEC on March&#160;28, 2024 and declared effective on May&#160;1, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Inducement Warrants will have an exercise price of $2.00 per share,
will be exercisable immediately and will expire on the five-year anniversary of their issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company engaged A.G.P./Alliance Global Partners
(&#8220;A.G.P.&#8221;) and Maxim Group LLC (&#8220;Maxim&#8221;, and together with A.G.P., the &#8220;Financial Advisors&#8221;) to act
as Financial Advisors in connection with the transactions summarized above and will pay the Financial Advisors an aggregate fee equal
to 5.75% of the gross proceeds raised in the transaction and reimburse the Financial Advisors for legal expenses incurred in connection
with the transaction not to exceed $60,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Inducement Agreement, for a period
of 75 days following the date of the Inducement Agreement, the Company may not (i)&#160;issue, enter into any agreement to issue, or announce
the issuance or proposed issuance of any shares of common stock or common stock equivalents, or (ii)&#160;file any registration statement
or any amendment or supplement thereto, except for (a)&#160;any prospectus or prospectus supplements, or (b)&#160;a registration statement
on Form&#160;S-8 related to employee benefit plans. These restrictions are subject to customary exceptions for &#8220;Exempt Issuances.&#8221;
Additionally, for a period of 12 months following the date of the Inducement Agreement, the Company is prohibited from effecting or entering
into any agreement to effect a Variable Rate Transaction (as defined in the Inducement Agreement), which includes any issuance of securities
of the Company or any of its subsidiaries with conversion or exercise prices that vary with the market price of the Company&#8217;s common
stock, or any equity line of credit or &#8220;at-the-market&#8221; offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The March&#160;Warrants and the underlying shares
of Common Stock were registered pursuant to the Company&#8217;s Registration Statement on Form&#160;S-3 (File No.&#160;333-278337), filed
with the SEC under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), on March&#160;28, 2024, which was declared
effective on May&#160;1, 2024. The August&#160;Warrants and the underlying shares of Common Stock were registered pursuant to the Company&#8217;s
Registration Statement on Form&#160;S-3 (File No.&#160;333-278334), filed with the SEC under the Securities Act on March&#160;28, 2024,
which was declared effective on May&#160;1, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing descriptions of the Inducement Agreement and the Inducement
Warrants do not purport to be complete and are qualified in their entirety by reference to the full text of the forms of Inducement Agreement
and Inducement Warrants, which are filed as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form&#160;8-K and incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the filing of the Inducement Agreement, the Company
is filing as Exhibit&#160;5.1 hereto an opinion of its counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., regarding the legality
of the Inducement Warrants and the Inducement Warrant Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01. Other Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October&#160;27, 2025, the Company issued a
press release (the &#8220;Press Release&#8221;) announcing the warrant inducement transaction. A copy of the Press Release is attached
hereto as Exhibit&#160;99.1 and is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;Number</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 87%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2529505d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2529505d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Inducement
    Warrant</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2529505d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2529505d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Mintz, Levin,
    Cohn, Ferris, Glovsky and Popeo, P.C.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2529505d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2529505d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Inducement
    Agreement</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2529505d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2529505d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Mintz, Levin,
    Cohn, Ferris, Glovsky and Popeo, P.C. (contained in exhibit 5.1)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2529505d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2529505d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated October&#160;27,
    2025</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104 </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive
    Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SELLAS Life Sciences Group,&#160;Inc.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October&#160;27, 2025</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ John T. Burns</i></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; width: 5%">&#160;</td>
    <td style="vertical-align: bottom; width: 45%">&#160;</td>
    <td style="vertical-align: bottom; width: 3%">&#160;</td>
    <td style="vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="vertical-align: top; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John T. Burns</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2WUy3IvAxsYgsQiJ6XXKMJd2R2a3sk/rLNiUaBobh3nOvEKFY00o3yHBelgUcse0a5RBKrJHRXNA7ss02BX9LvGrrWBk3vD8wI8+gZ+aRnCkvDNaHtlilkMSTeDqRM0hkOl/AYSeCr56RqXWFxmnVgDIVHJg61ugUv8aEo+rJUPsaqk7IVpPxcVE8ym+QcSJhTw/1JL5ZKIpMBOEwgVgz3TvvynuH5ktC3mDr6+xI/zf4AAbJSo0= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm2529505d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANT TO PURCHASE SHARES OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SELLAS
Life Sciences Group,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares:</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance Date: _______, 2025</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Exercise Date: _______, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS WARRANT TO PURCHASE
SHARES OF COMMON STOCK (this &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m.&nbsp;(New York City Time) on [&bull;],
2030<SUP>1 &nbsp;</SUP>(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from SELLAS Life
Sciences Group,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to _______ shares of Common Stock, par value
$0.0001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), of the Company (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Warrant Inducement Agreement
(the &ldquo;<U>Inducement Agreement</U>&rdquo;), dated October&nbsp;24, 2025, between the Company and the purchaser signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as&nbsp;<B>Exhibit&nbsp;A</B>&nbsp;(the
&ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i)&nbsp;one (1)&nbsp;Trading Day and (ii)&nbsp;the number of Trading
Days comprising the Standard Settlement Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below
is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares
available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company
for cancellation within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the
effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice.&nbsp;<B>The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
Price</U>. The exercise price per share of Common Stock of this Warrant shall be $2.00, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> Insert 5 year anniversary of the Issuance Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Cashless
Exercise</U>. Notwithstanding anything to the contrary set forth herein, if at the time of exercise hereof there is no effective registration
statement registering the issuance of the Warrant Shares to the Holder, or the prospectus contained therein is not available for the issuance
of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)&nbsp;=</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either (x)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (y)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)&nbsp;=</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)&nbsp;=</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If Warrant Shares are issued
in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities Act,
the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position
contrary to this Section&nbsp;2(c), except to the extent required by a change in applicable law, rules&nbsp;or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.&nbsp;(New York
City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holder of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.&nbsp;(New
York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock
so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything herein
to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section&nbsp;2(c),
subject to the limitations in Section&nbsp;2(e)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;<U>Mechanics
of Exercise.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with DTC through its Deposit
or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A)&nbsp;there
is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder
or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of the Warrant Shares, registered
in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest
of (i)&nbsp;one (1)&nbsp;Trading Day after the delivery to the Company of the Notice of Exercise, and (ii)&nbsp;the number of Trading
Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
within the earlier of (i)&nbsp;one (1)&nbsp;Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period
following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
to a Notice of Exercise by the Warrant Share Delivery Date applicable to such exercise, the Holder may upon written demand to the Company
require the Company to pay (and the Company shall pay) to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10
per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day
after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to
maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used
herein, &ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number of Trading Days (including
no Trading Days if the settlement date is the trade date), on the Company&rsquo;s primary Trading Market with respect to the Common Stock
as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise
delivered on or prior to 12:00 p.m.&nbsp;(New York City time) on the Initial Exercise Date, which may be delivered at any time after the
time of execution of the Inducement Agreement, the Company agrees to deliver, or cause to be delivered, the Warrant Shares subject to
such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant
Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless
exercise) is received by such Warrant Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering written notice to the Company
at any time prior to the Company delivering such Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date (other than any failure solely due to any action or inaction by the
Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market transaction
or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by
the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company
shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number
of Warrant Shares that the Company was required to deliver, but did not timely deliver, to the Holder in connection with the exercise
at issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option
of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have
been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock
with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Charges,
Taxes and Expenses</U>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form&nbsp;attached hereto as&nbsp;<B>Exhibit&nbsp;B</B>, duly executed
by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees
to DTC (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial ownership
shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that
the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises
of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other than to the extent that information on the
number of outstanding shares of Common Stock is provided by the Company, either directly or through one or more public filings, and relied
upon by the Holder). In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated thereunder and the Company shall have no obligation
to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that are not in compliance
with the Beneficial Ownership Limitation (other than to the extent that information on the number of outstanding shares of Common Stock
is provided by the Company, either directly or through one or more public filings, and relied upon by the Holder). For purposes of this
Section&nbsp;2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares
of Common Stock as reflected in (A)&nbsp;the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case
may be, (B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer
Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall
within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case,
the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of
the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of
outstanding shares of Common Stock was reported. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be [4.99%/9.99%] of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder
and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership Limitation will not
be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph (or
any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant),
(ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of shares of
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or reclassification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>[RESERVED]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (other than dividends or distributions subject to Section&nbsp;3(a))
(a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled
to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (provided, however, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would
result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution
to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the
portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would
not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (or any Subsidiary),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of the consolidated assets of the Company in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase
offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of
more than 50% of the outstanding Common Stock or more than 50% of the outstanding voting power of the common equity of the Company, (iv)&nbsp;the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a
stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off,
merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of
the outstanding shares of Common Stock or more than 50% of the outstanding voting power of the common equity of the Company (each, a &ldquo;Fundamental
Transaction&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the &ldquo;Alternate Consideration&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price
shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect
of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below)
shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of
the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this
Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining
unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental
Transaction is not within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be
entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the
Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company
in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or
whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the
Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in
such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;Black Scholes Value&rdquo;
means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable contemplated Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the 100 day volatility
obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following
the public announcement of the applicable contemplated Fundamental Transaction, (C)&nbsp;the underlying price per share used in such calculation
shall be the greater of (i)&nbsp;the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration,
if any, being offered in such Fundamental Transaction and (ii)&nbsp;the highest VWAP during the five (5)&nbsp;trading days immediately
prior to the consummation of such Fundamental Transaction and (D)&nbsp;a remaining option time equal to the time between the date of the
public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E)&nbsp;a zero cost of borrow.
The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within
the later of (i)&nbsp;five Business Days of the Holder&rsquo;s election and (ii)&nbsp;the date of consummation of the Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;Successor
Entity&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance
with the provisions of this Section&nbsp;3(e)&nbsp;pursuant to written agreements in form and substance reasonably satisfactory to the
Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>[RESERVED]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the
case may be. For purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice to Allow Exercise by Holder</U>. If, while the Warrant is outstanding, (A)&nbsp;the Company declares a dividend (or any other distribution in whatever form) on the shares of Common Stock, (B)&nbsp;the Company declares a cash dividend on, or a redemption of, the shares of Common Stock, (C)&nbsp;the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company is required in connection with a Fundamental Transaction, or (E)&nbsp;the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
[Reserved],</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;5. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant, substantially in the form attached hereto as&nbsp;<B>Exhibit&nbsp;B</B>, duly executed by the Holder or its agent or attorney
and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment,
the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this
Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall
not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case,
the Holder shall surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an
assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;5(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Currency</U>.
All dollar amounts referred to in this Warrant are in United States Dollars (&ldquo;<U>U.S. Dollars</U>&rdquo;). All amounts owing under
this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent
amount in accordance with the Exchange Rate on the date of calculation. &ldquo;<U>Exchange Rate</U>&rdquo; means, in relation to any amount
of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street
Journal (NY edition) on the relevant date of calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Authorized
Shares</U>. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued
shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying the Warrant upon the
exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full
authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights
under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued,
as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the
Common Stock may be listed. The Company covenants that all Warrant Shares underlying this Warrant, which may be issued upon the exercise
of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment
for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Except and to the extent as
waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company
will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Inducement Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Inducement Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Inducement Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any shares of Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Signature Page&nbsp;Follows)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SELLAS Life Sciences Group,&nbsp;Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO: SELLAS LIFE SCIENCES GROUP,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;The undersigned hereby
elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;Payment shall take
the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Wingdings; color: #0070c0"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;Please issue said
Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE OF HOLDER]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity:&nbsp;<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:&nbsp;<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:&nbsp;<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:&nbsp;<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;<U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone Number:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2529505d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 50%"><IMG SRC="tm2529505d1_ex5-1img001.jpg" ALT=""></TD>
    <TD STYLE="text-align: right; width: 50%; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">919 Third Avenue</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212 935 3000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">mintz.com</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">October&nbsp;27, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SELLAS Life Sciences Group,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7 Times Square, Suite&nbsp;2503</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as legal counsel
to SELLAS Life Sciences Group,&nbsp;Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the preparation and filing
with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) of a Prospectus Supplement, dated October&nbsp;24, 2025 (the
&ldquo;Prospectus Supplement&rdquo;), to a Registration Statement (File No.&nbsp;333-278334) on Form&nbsp;S-3 (the &ldquo;Registration
Statement&rdquo;), filed by the Company with the Commission under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).
The Prospectus Supplement relates to the sale of warrants (the &ldquo;Warrants&rdquo;) to purchase up to 22,363,714 shares (the &ldquo;Warrant
Shares&rdquo;) of the Company&rsquo;s common stock, $0.0001 par value per share (the &ldquo;Common Stock&rdquo;), pursuant to the Inducement
Agreement, dated October&nbsp;24, 2025, between the Company and an investor (the &ldquo;Inducement Agreement&rdquo;). The form of Inducement
Agreement will be filed as an exhibit to a Current Report on Form&nbsp;8-K and incorporated by reference into the Registration Statement.
This opinion is being rendered in connection with the filing of the Prospectus Supplement with the Commission. All capitalized terms used
herein and not otherwise defined shall have the respective meanings given to them in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this opinion,
we have examined the Company&rsquo;s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as currently
in effect, the Registration Statement and the exhibits thereto, the Prospectus Supplement and the Inducement Agreement and such other
records of the corporate proceedings of the Company and certificates of the Company&rsquo;s officers as we have deemed relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our examination, we have
assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as
originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies and the authenticity
of the originals of such copies. With respect to our opinion as to the shares of Common Stock issuable upon exercise of the Warrants,
we have assumed that, at the time of issuance and sale, a sufficient number of shares of Common Stock are authorized and available for
issuance under the Company&rsquo;s Amended and Restated Certificate of Incorporation as then in effect and that the exercise price per
share of the Warrants is an amount that is not less than the par value of the Common Stock. We have relied, without independent verification,
on certificates of public officials and, as to matters of fact material to the opinions set forth below, on certificates of officers of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: left; width: 50%; vertical-align: top">
    <FONT><B>MINTZ</B></FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT>October&nbsp;27, 2025</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT>Page&nbsp;2</FONT></P></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right; width: 50%"><IMG SRC="tm2529505d1_ex5-1img002.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our opinion is limited to the General Corporation
Law of the State of Delaware, and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein
with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon the foregoing,
we are of the opinion that (i)&nbsp;the Warrants, if and when paid for in accordance with the terms of the Registration Statement and
the Inducement Agreement, will constitute valid and legally binding obligations of the Company, except as may be limited by bankruptcy,
insolvency or other similar laws affecting the rights and remedies of creditors in general and the general principles of equity and (ii)&nbsp;with
respect to Warrant Shares issuable upon exercise of the Warrants when the exercise price is paid in full and the Warrant Shares are issued
in accordance with the terms and conditions of the Warrants, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please note that we are opining
only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon
currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in
any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We understand that you wish
to file this opinion with the Commission as an exhibit to a Current Report on Form&nbsp;8-K for incorporation by reference into the Registration
Statement in accordance with the requirements of Item 601(b)(5)&nbsp;of Regulation S-K promulgated under the Securities Act and to reference
the firm&rsquo;s name under the caption &ldquo;Legal Matters&rdquo; in the Prospectus Supplement, and we hereby consent thereto. In giving
this consent, we do not admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities
Act or the rules&nbsp;and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mintz, Levin, Cohn, Ferris,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glovsky and Popeo, P.C.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>tm2529505d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SELLAS Life Sciences Group,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">7 Times Square, Suite&nbsp;2503</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, NY 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October&nbsp;24, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Holder of Common Stock Purchase Warrants Issued on March&nbsp;19,
2024 and August&nbsp;1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: Inducement Offer to Exercise Existing Shares of Common Stock Purchase
Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SELLAS Life Sciences Group,&nbsp;Inc. (the &ldquo;<U>Company</U>&rdquo;)
is pleased to offer (this &ldquo;<U>Inducement Offer</U>&rdquo;) to you (&ldquo;<U>Holder</U>&rdquo;, &ldquo;<U>you</U>&rdquo; or similar
terminology) the opportunity to receive new registered common stock purchase warrants (the &ldquo;<U>New Warrants</U>&rdquo;) to purchase
up to 22,363,714 shares of the Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;<U>Common Stock</U>&rdquo;), which
is equal to 100% of the number of shares of Common Stock issuable upon exercise of (i)&nbsp;a purchase warrant to purchase up to 6,514,658
shares of Common Stock at an exercise price of $1.41 per share issued to you on March&nbsp;19, 2024 (the &ldquo;<U>March&nbsp;Warrants</U>&rdquo;),
and (ii)&nbsp;a purchase warrant to purchase up to 15,849,056 shares of Common Stock at an exercise price of $1.20 per share issued to
you on August&nbsp;1, 2024 (the &ldquo;<U>August&nbsp;Warrants</U>&rdquo; and together with the March&nbsp;Warrants, the &ldquo;<U>Existing
Warrants</U>&rdquo;), as more particularly set forth on the signature page&nbsp;hereto, in consideration for exercising for cash all such
Existing Warrants. The issuance, or resale, of the shares of Common Stock issuable upon exercise of the March&nbsp;Warrants have been
registered pursuant to the Company&rsquo;s effective registration statement on Form&nbsp;S-3 (File No.&nbsp;333-278337) and the shares
of Common Stock issuable upon exercise of the August&nbsp;Warrants have been registered pursuant to the Company&rsquo;s effective registration
statement on Form&nbsp;S-3 (File No.&nbsp;333-278334). The shares of Common Stock underlying the Existing Warrants are referred to herein
as the &ldquo;<U>Warrant Shares</U>&rdquo; and the effective registration statements on Form&nbsp;S-3 referenced in the foregoing sentence
are referred to herein as the &ldquo;<U>Registration Statements</U>.&rdquo; The Registration Statements are currently effective and, upon
exercise of the Existing Warrants pursuant to this letter agreement, will remain effective for the resale of the Warrant Shares. Capitalized
terms not otherwise defined herein shall have the meanings set forth in the New Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is making you this offer during the
period from the date of this Inducement Offer set forth above and until 9:00 a.m.&nbsp;Eastern Time, on October&nbsp;27, 2025 (the &ldquo;<U>Exercise
Period</U>&rdquo;). Exercise of the Existing Warrants may be made, in whole or in part, at any time or times during the Exercise Period
by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise
attached to the Existing Warrants, as applicable; <I><U>provided</U></I>, that the exercise of Existing Warrants will be accompanied by
payment in full of the Exercise Price (as defined below) to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to comply with the rules&nbsp;and regulations
of the Nasdaq Capital Market, the Holder hereby agrees to exercise the March&nbsp;Warrants at an exercise price of $1.535 per share and
the August&nbsp;Warrants at an exercise price of $1.325 per share. In consideration for exercising the Existing Warrants held by the Holder,
and each time that the Holder exercises Existing Warrants pursuant to the terms of this Offer (the &ldquo;<U>Warrant Exercise</U>&rdquo;)
during the Exercise Period, the Company hereby offers to issue you or your designees registered New Warrants to purchase up to 22,363,714
New Warrant Shares, which equals 100% of the number of Warrant Shares issued pursuant to the exercise of the Existing Warrants, which
New Warrants shall be registered and issued pursuant to a prospectus supplement (the &ldquo;<U>Prospectus</U>&rdquo;) relating to the
Company&rsquo;s effective registration statement on Form&nbsp;S-3 (File No.&nbsp;333-278334) under the Securities Act of 1933, as amended
(&ldquo;<U>Securities Act</U>&rdquo;), which New Warrants shall be substantially in the form as set forth in <B><U>Exhibit&nbsp;A</U></B>
hereto. The New Warrants will be exercisable immediately and the issuance of all of the Warrant Shares upon exercise thereof, have an
exercise price of $2.00 per share and have a term of exercise of five (5)&nbsp;years from the date of issuance. The New Warrants certificates
will be delivered within one (1)&nbsp;Trading Day following the Warrant Exercise. Notwithstanding anything herein to the contrary, in
the event that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (&ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo;) set forth in Section&nbsp;2(e)&nbsp;of the Existing Warrants (or, if applicable and at the Holder&rsquo;s
election, 9.99%), the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the
maximum number of Warrant Shares permitted thereunder, as directed by the Holder, with the balance to be held in abeyance until notice
from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced
through the Existing Warrants which shall be deemed prepaid thereafter (including the payment in full of the exercise price), and exercised
pursuant to a Notice of Exercise in the Existing Warrants (provided no additional exercise price shall be due and payable). The parties
hereby agree that the Beneficial Ownership Limitation for purposes of the Existing Warrants is as set forth on the Holder&rsquo;s signature
page&nbsp;hereto. Expressly subject to the paragraph immediately following this paragraph below, the Holder may accept this offer by signing
this letter below, which constitutes the Holder&rsquo;s acceptance to exercise Existing Warrants in full for an aggregate price of $30,999,999.23,
subject to the Beneficial Ownership Limitation set forth in Section&nbsp;2(e)&nbsp;of the Existing Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company agrees to the representations,
warranties and covenants set forth on <B><U>Annex A</U></B> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Holder represents and warrants that, as
of the date hereof, the Holder is fully aware of, and has reviewed all of the Company&rsquo;s public filings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the New Warrants,
the Holder hereby waives its rights with respect to the prohibition on the issuance of securities pursuant to Section&nbsp;(h)&nbsp;of
Annex A to that certain Warrant Inducement Agreement dated as of September&nbsp;10, 2025, by and between the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this offer is accepted and this offer letter
is executed, then on or before 8:30 a.m., Eastern Time, on the Trading Day following the date hereof, the Company shall issue a press
release and/or file a Current Report on Form&nbsp;8-K with the Commission disclosing all material terms of the transactions contemplated
hereunder, including this letter agreement as an exhibit thereto with the Commission. From and after the issuance of such press release
or filing of such Current Report on Form&nbsp;8-K, as applicable, the Company represents to you that it shall have publicly disclosed
all material, non-public information delivered to you by the Company, or any of its respective officers, directors, employees or agents
in connection with the transactions contemplated hereunder. In addition, effective upon the issuance of such press release and/or filing
of such Current Report on Form&nbsp;8-K, the Company acknowledges and agrees that any and all confidentiality or similar obligations under
any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents,
employees or Affiliates on the one hand, and you and your Affiliates on the other hand, shall terminate. The Company represents, warrants
and covenants that, upon acceptance of this offer, and upon issuance of the Warrant Shares, the Warrant Shares shall be issued free of
any legends or restrictions on resale by Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No later than the first (1<FONT STYLE="font-size: 10pt"><SUP>st</SUP></FONT>)
Trading Day following the date hereof, the closing (&ldquo;<U>Closing</U>&rdquo;) shall occur at such location as the parties shall mutually
agree. Unless otherwise directed by A.G.P./Alliance Global Partners. (the &ldquo;<U>Financial Advisor</U>&rdquo;), settlement of the Warrant
Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company shall
issue the Warrant Shares registered in the Holder&rsquo;s name and address provided to the Company in writing and released by the Transfer
Agent directly to the account(s)&nbsp;at the Financial Advisor identified by the Holder; upon receipt of such Warrant Shares, the Financial
Advisor shall promptly electronically deliver such Warrant Shares to the Holder, and payment therefor shall concurrently be made to the
Company by the Financial Advisor (or its clearing firm) by wire transfer to the Company). The date of the Closing of the exercise of the
Existing Warrants shall be referred to as the &ldquo;<U>Closing Date</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Governing Law</U>. All questions concerning
the construction, validity, enforcement and interpretation of this letter agreement shall be governed by and construed and enforced in
accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees
that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this letter agreement
and the New Warrant (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners,
members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein
(including with respect to the enforcement of any of this letter agreement and the New Warrant), and hereby irrevocably waives, and agrees
not to assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such action or proceeding by mailing a copy thereof via registered or certified
mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an action or proceeding
to enforce any provisions of this letter agreement or the New Warrant, then, in addition to the obligations of the Company under the following
paragraph, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Indemnification</U>. Subject to the provisions
of this paragraph, the Company will indemnify and hold each Holder and its directors, officers, shareholders, members, partners, employees
and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title), each Person who controls each Holder (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20
of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a
functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling
persons (each, a &ldquo;<U>Holder Party</U>&rdquo;) harmless from any and all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and
costs of investigation that any such Holder Party may suffer or incur as a result of or relating to (a)&nbsp;any material breach of any
of the representations, warranties, covenants or agreements made by the Company in this offer letter or the New Warrant or (b)&nbsp;any
action instituted against each Holder Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the
Company who is not an Affiliate of such Holder Party, with respect to any of the transactions contemplated by this offer letter or the
New Warrant (unless such action is solely based upon a material breach of such Holder Party&rsquo;s representations, warranties or covenants
under this offer letter or any agreements or understandings such Holder Party may have with any such stockholder or any violations by
such Holder Party of state or federal securities laws or any conduct by such Holder Party which is finally judicially determined to constitute
fraud, gross negligence or willful misconduct), or (c)&nbsp;in connection with the Registration Statements, the Company will indemnify
each Holder Party, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities,
costs (including, without limitation, reasonable attorneys&rsquo; fees) and expenses, as incurred, arising out of or relating to (i)&nbsp;any
untrue or alleged untrue statement of a material fact contained in the Registration Statements, any prospectus or any form of prospectus
or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission
of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement
thereto, in the light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that
such untrue statements or omissions are based solely upon information regarding such Holder Party furnished in writing to the Company
by such Holder Party expressly for use therein, or (ii)&nbsp;any violation or alleged violation by the Company of the Securities Act,
the Exchange Act or any state securities law, or any rule&nbsp;or regulation thereunder in connection therewith. If any action shall be
brought against any Holder Party in respect of which indemnity may be sought pursuant to this Agreement, such Holder Party shall promptly
notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably
acceptable to each Holder Party. Any Holder Party shall have the right to employ separate counsel in any such action and participate in
the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Holder Party except to the extent that
(x)&nbsp;the employment thereof has been specifically authorized by the Company in writing, (y)&nbsp;the Company has failed after a reasonable
period of time to assume such defense and to employ counsel or (z)&nbsp;in such action there is, in the reasonable opinion of counsel,
a material conflict on any material issue between the position of the Company and the position of such Holder Party, in which case the
Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable
to any Holder Party under this Agreement (1)&nbsp;for any settlement by a Holder Party effected without the Company&rsquo;s prior written
consent, which shall not be unreasonably withheld or delayed; or (2)&nbsp;to the extent, but only to the extent that a loss, claim, damage
or liability is attributable to any Holder Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made
by such Holder Party in this offer letter or the New Warrant. The indemnification required by this paragraph shall be made by periodic
payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred; provided,
however, that if it is subsequently determined by a final, non-appealable judgment of a court of competent jurisdiction that each Holder
was not entitled to receive such payments, each Holder shall promptly (but in no event later than five (5)&nbsp;Business Days) return
such payments to the Company. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of
any Holder Party against the Company or others and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Person</U>&rdquo; means an individual
or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock
company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page&nbsp;follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sincerely yours,</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SELLAS Life Sciences Group,&nbsp;Inc.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SELLAS Life Sciences Group,&nbsp;Inc. Signature
Page&nbsp;to Warrant Inducement Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>HOLDER
SIGNATURE PAGE TO<BR>
SELLAS Life Sciences Group,&nbsp;Inc. Warrant Inducement Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and Agreed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Holder: _______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Signature of Authorized Signatory of Holder</I>: _________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Authorized Signatory:____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title of Authorized Signatory: _____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of March&nbsp;Warrants:_________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of August&nbsp;Warrants:_________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aggregate Warrant Exercise Price being exercised contemporaneously
with signing this letter agreement:______________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">March&nbsp;Warrants
Beneficial Ownership Blocker: </FONT><FONT STYLE="font-family: Wingdings">&#168;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">4.99%
or <FONT STYLE="font-family: Wingdings">&#168;</FONT> 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">August&nbsp;Warrants
Beneficial Ownership Blocker: </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">4.99%
or <FONT STYLE="font-family: Wingdings">&#168;</FONT> 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New Warrants: (up to 100% of total Existing Warrants being exercised):____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
Warrants Beneficial Ownership Blocker: <FONT STYLE="font-family: Wingdings">&#168;</FONT> 4.99% or </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DTC Instructions:_______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Holder Signature Page&nbsp;to SELLAS Life Sciences
Group,&nbsp;Inc. Warrant Inducement Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Representations, Warranties and Covenants of
the Company</I>. The Company hereby makes the following representations and warranties to the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>SEC Reports</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein &ldquo;<U>SEC Reports</U>&rdquo;). As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading except as otherwise noted in a subsequent SEC Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection herewith, if applicable. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law. The New Warrants and New Warrant Shares are duly authorized and the New Warrant Shares, when issued and paid for in accordance with the terms of this letter and the New Warrants, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company. The New Warrants constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except: (i)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general principles of equity.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>No Conflicts</U>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s certificate or articles of incorporation, bylaws or other organizational or charter documents; or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any liens, claims, security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii)&nbsp;conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii)&nbsp;and (iii), such as could not have or reasonably be expected to result in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations under this letter agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Trading Market</U>. The transactions contemplated under this letter agreement comply with all the rules&nbsp;and regulations of the Nasdaq Capital Market.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of this letter agreement, other than: (i)&nbsp;the filings required pursuant to this letter agreement; and (ii)&nbsp;application(s)&nbsp;or notice to each applicable Trading Market for the listing of the New Warrants and New Warrant Shares for trading thereon in the time and manner required thereby.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Listing of Shares of Common Stock</U>. The Holder is fully aware of, and has reviewed all of the Company&rsquo;s public filings on EDGAR since January&nbsp;1, 2024. The Company agrees, if the Company applies to have the Shares of Common Stock traded on any other Trading Market, it will then include in such application all of the New Warrant Shares, and will take such other action as is necessary to cause all of the New Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Shares of Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules&nbsp;of the Trading Market. The Company agrees to maintain the eligibility of the Shares of Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Subsequent Equity Sales</U>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">i.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until seventy-five (75) days following the date of this letter agreement, neither the Company nor any Subsidiary shall (A)&nbsp;issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Shares of Common Stock or Shares of Common Stock Equivalents or (B)&nbsp;file any registration statement or any amendment or supplement to any existing registration statement (other than the filing of (x)&nbsp;any prospectus or prospectus supplement, or (y)&nbsp;a registration statement on Form&nbsp;S-8 in connection with any employee benefit plan); provided, however, the Company may enter into this Inducement Agreement and any other inducement agreement entered into by other holders of Existing Warrants with respect to the inducement offer being made herein. Notwithstanding the foregoing, this Section&nbsp;(i)(i)&nbsp;shall not apply in respect of an Exempt Issuance. &ldquo;<U>Exempt Issuance</U>&rdquo; means the issuance of (a)&nbsp;shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b)&nbsp;securities upon the exercise or exchange of or conversion of any securities issued hereunder and/or any securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c)&nbsp;securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in this Section&nbsp;(i)(i), and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. &ldquo;<U>Person</U>&rdquo; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ii.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until twelve (12) months following the date of this letter agreement, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Shares of Common Stock or Shares of Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company (i)&nbsp;issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional Shares of Common Stock either (A)&nbsp;at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Shares of Common Stock at any time after the initial issuance of such debt or equity securities, or (B)&nbsp;with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Shares of Common Stock or (ii)&nbsp;enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at the market offering&rdquo;, whereby the Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently canceled. The Holder shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages. &ldquo;<U>Shares of Common Stock Equivalents</U>&rdquo; means any securities of the Company or its subsidiaries which would entitle the holder thereof to acquire at any time Shares of Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Shares of Common Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">iii.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding the foregoing, this Section&nbsp;(i)&nbsp;shall not apply in respect of an Exempt Issuance.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">iv.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Holder consents to the use of the proceeds from the exercise of the Existing Warrants to settle outstanding litigation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(j)</TD><TD STYLE="text-align: justify"><U>Issuance of the Securities; Registration</U>. The New Warrants
are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued,
free and clear of all liens imposed by the Company. The New Warrant Shares, when issued pursuant to the terms of the New Warrants, will
be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company. The Company has reserved
from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to the exercise of the New Warrants.
The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became
effective on May&nbsp;1, 2024, including a prospectus, and such amendments and supplements thereto as may have been required to the date
of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness
of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings
for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required
by the rules&nbsp;and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule&nbsp;424(b). At the
time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the
Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at
the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all
material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form&nbsp;S-3. The Company
is eligible to use Form&nbsp;S-3 under the Securities Act and it meets the transaction requirements pursuant to General Instruction I.B.1
of Form&nbsp;S-3.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of New Registered Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>tm2529505d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>SELLAS Life Sciences
Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">NEW YORK, Oct.&nbsp;27,
2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group,&nbsp;Inc. (NASDAQ: SLS) (&ldquo;SELLAS&rdquo; or the &ldquo;Company&rdquo;), a late-stage
clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced
the immediate exercise of warrants, previously issued in March&nbsp;and August&nbsp;2024 (the &ldquo;Existing Warrants&rdquo;), to purchase
up to 22,363,714 shares of its common stock for gross cash proceeds of approximately $31.0 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">In consideration
for the immediate exercise in full of the Existing Warrants, the investor will receive new registered warrants to purchase up to 22,363,714
shares of its common stock (the &ldquo;New Warrants&rdquo;) at an exercise price of $2.00, will be exercisable immediately and will expire
five years from the date of issuance. The closing of this transaction is expected to occur on or about October&nbsp;28, 2025, subject
to satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">A.G.P./Alliance
Global Partners and Maxim Group LLC acted as financial advisors in connection with the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The shares of common
stock issuable upon the exercise of the Existing Warrants has been registered pursuant to effective registration statements on Form&nbsp;S-3
(File No.&nbsp;333-278337 and File No.&nbsp;333-278334).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The offering is
being made pursuant to an effective shelf registration statement on Form&nbsp;S-3 (File No.&nbsp;333-278334) previously filed with the
U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;). A prospectus supplement describing the terms of the proposed offering
will be filed with the SEC and will be available on the SEC&rsquo;s website located at http://www.sec.gov. Electronic copies of the prospectus
supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022,
or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">SELLAS will host
a virtual R&amp;D Day on Wednesday, October&nbsp;29, 2025 at 10:00 AM ET, featuring key opinion leaders (KOLs), alongside company management,
to discuss the unmet medical need and evolving treatment landscape for acute myeloid leukemia (AML). To register, <U>click here</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This press release
does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in this offering, nor shall there be
any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About SELLAS
Life Sciences Group,&nbsp;Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">SELLAS is a late-stage
clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS&rsquo;
lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in
an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic
malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class
differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests
that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly
associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This press release
contains forward-looking statements. All statements other than statements of historical facts are &ldquo;forward-looking statements,&rdquo;
including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as &ldquo;plan,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;project,&rdquo;
&ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;continue&rdquo;
and other words or terms of similar meaning. These statements include, without limitation, statements related to our ability to close
the offering, the gross proceeds from the offering and the expected use of proceeds. These forward-looking statements are based on current
plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results
and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks
and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success
thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set
forth under the caption &ldquo;Risk Factors&rdquo; in SELLAS&rsquo; Annual Report on Form&nbsp;10-K filed on March&nbsp;20, 2025 and
in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS&rsquo; forward-looking
statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements
herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to
reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date
as of which the forward-looking statements were made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Investor Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">John Fraunces</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Managing Director</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">LifeSci Advisors,
LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">jfraunces@lifesciadvisors.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>sls-20251024.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaSEqbOdzZR+qYkxtmBwbQm67yIlOtJV2SashtfmYQgN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:sls="http://sellaslifesciences.com/20251024" elementFormDefault="qualified" targetNamespace="http://sellaslifesciences.com/20251024">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://sellaslifesciences.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="sls-20251024_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="sls-20251024_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>sls-20251024_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>sls-20251024_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="sls-20251024.xsd#Cover" roleURI="http://sellaslifesciences.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sellaslifesciences.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2529505d1_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2529505d1_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "6 '@# 2(  A$! Q$!_\0
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MQ\%].\3^(;C3!X[TR272/%!L%6R>*^BYBG2VA>93:7?+6LDGE2N$;?!'T/\
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MT'_@J)M'Q\_X)V 1HV_]H5L$=!_Q)SUZ<8Z8SQ@G'./UC^)ZAOAS\0BVT_\
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M:DN9, *3U)((  I(?ACX"@.4\&>%.$MHBQT*R+21P=I R%3SRF0P'\8?L44
M=/INAZ5HT4L.DZ;8:=',_FS)8VMO9BZEVD;K@6\$88C. V&.">,$J2BB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2529505d1_ex5-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2529505d1_ex5-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !6 $$# 2(  A$! Q$!_\0
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MS3J*/,W&\?:23M;1M.5[>>NA_9OC)X*OB[Q X XX6&BX4J^73SW"U(4W"5'
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MEEU2C4C%86,7*2G[*VLU:^NQA6\C+&B(H$JQQ_: C!P)2HW@-T.'##('.#C
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FC"W[G4+/2;.VO54@;V\^&%'25CD,\94NF Y)%%% ':T444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 24, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 24,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS
Life Sciences Group, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8099512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Times Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">200-5278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2529505d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sellaslifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sls-20251024.xsd</File>
    <File>sls-20251024_lab.xml</File>
    <File>sls-20251024_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2529505d1_8k.htm">tm2529505d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2529505d1_8k.htm": {
   "nsprefix": "sls",
   "nsuri": "http://sellaslifesciences.com/20251024",
   "dts": {
    "schema": {
     "local": [
      "sls-20251024.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "sls-20251024_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sls-20251024_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2529505d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://sellaslifesciences.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-10-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2529505d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-10-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2529505d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://sellaslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-25-102345-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-102345-xbrl.zip
M4$L#!!0    ( '5$6UN8G4M$*P,  /T+   0    <VQS+3(P,C4Q,#(T+GAS
M9+5635/;,!"]=Z;_0?65L1TG!4I(8"B43CH!2E(H<.DH]B9HD"4CR23TUU>R
MK7PY"4G:^B2OWGN[J]V5W3@>Q12]@)"$LZ83>!4' 0MY1-B@Z=QTW9/N::OE
MH..C]^^0?AH?7!>=$Z!1'9WQT&VQ/C]$ESB&.OH*# 167!RB6TQ38^'GA()
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MD6SVB8-+]5L@]C:9R%N?R*?#*RO!H#5&5^JW#*0'J(#_&F-F:/"_<ZS3X>V
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M!N5&HW_:-0L?)$?R?5.;X>^1,]8/_A]02P,$%     @ =41;6\GMTP/G*P
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MI:A:D)_32AC964#21&(>R/ 3BI0@"143Y[DF-0GG0Y?M/+ZTNC0E*.$'5W.
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M7[+>9;OHD@9O+ECA2_9L,E:HU_LFM[T4PHU)2"#Y().<&DZXN^3J BF2[Y,
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M'1$-5UE1[PK"U_-@Z(:D.'$I'K:]B="20UYSJ;FL6:0+)OH"XI*9'%<V)N*
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M[]L1PI.##X>_$P?]Y>S7=WO_#U!+ P04    " !U1%M;W*SN<JA#   /;P$
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MRUYE3??7D+HQO7<9U5G3K0U"B#IMK'M+=5&2Q=G."&S3L^I9=_ UC2X_;:M
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M175S;3\5OO9,%:I*<B=+&V_Y64FDY) >,EM8A?$3B56,"@F[].9)Y2.@A16
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M=+-#>;3W_N!O2 ./WIS^]/;5_P=02P,$%     @ =41;6QEJR,/^"@  !BP
M !4   !T;3(U,CDU,#5D,5]E>#4M,2YH=&W=6FUOVS@2_F[ _X%GW!8M(#N.
MW;3;) V0M[;!NFD0&]OK?3G0$FUS*XDJ125U?_T]0U*RG"II<^L<@N:#8TGD
MS'#FF5=Y_]WD_>B@W=I_=WIX@O^,_O8G9Y/1Z<'^EON/IUO^\?[1AY-/;#SY
M-#I]W9FIU.RR[7YFV$0F(F?GXII=JH2G@;L1L+'0<M;!1FR]N.^^/99P/9?I
M+J.E_3UFQ%?3Y;&<XY:6\X7I'#Q)IWFVM[]U\8 \]H\.3O_U[NSH;,)V>MO[
M6T<'&^/WW0$FAT>C4W9\.AJ-+PZ/S\[?ON[T._;ZXO#DI+R^-]-K&9D%+>W_
MML>F2D="=T,5QSS+Q2XKOW4L /8GER6#*Z&-#'E<*L2HK.-!LC\Y*5?551:*
MU A=,=SI_P;]G;U_R\:7QUB9#'8&KW;Z.]'V?\37G>ZV3.;]_G;OKVS>88>C
MR>M.AU!W<C</:Y8ZBSW6*.@&K/-J^Q6;+*2.V.&52 OA[&1E^_O$:=TGI3\'
M[/P3F68PV"CYP?: O1KNL&&_W]\HX42FYELO5 E1M>;"QZ7#SI8%\,'&7='A
MZO_C[Q]"HZ9".U:#EP$;] <[#^?R?Y_@&.'A<,Q&<B;8.)0B#;'YK59%%CA>
M9VG8VR"_EW[]^$O!M<"J0AKAU;73'VZ04\U%_#=RE.&+QVR-$8\DEO,T8F^!
MVE@D(MU]O *ON\!?16[D;.EORC021+3?VY%IY^"C8 M^)1@/C8@8SUDLYCQ&
M^BC27,3MEE'LIZ 8,,Y.1,RO@1[LUIG2W$B5LJ=F(=B3./I2J+UCE60\73[1
M]NI9P&2*M6DJ0KOT6IH%H^69%AGW^TGG,QG+=-YN50O&(BRT-*5-3K^&"Y[.
M!0.#1.9Y U]_NV3-U P"7VB59V!> /=%EEFSFH!%G'2Q'C*>NY!AR;9;GF[C
M_M7IH#O.+L5<YL8?9FQ FA:QIV]D+-BYZCGZP^&P.WCY^W#X'**E[(W2B7LP
M[@[7CE(GUVY5]%9,H2L(/UU:/7F%KS1;4U !(.B;VCP,#:EF^]5P&! :.(A'
MH%<787UYR;G7;DVPIE$E3 ,9!NNA$2*4<YP=;  6S5.3KY'_Z&]6IL*FK-"P
M<"Y8D='E8! ,7PR#E]O/6;X X!H)0#OV6=WD-9T\T3G=S@' )($Z<J-"Q*1_
M]GO(K=L,^&-7/"X 1FC)<OD.4M:@V+52/N3,"_ N#WJ61D5H5=!N'<ZU^#'
M C85YEJ(=,U^!'*>PEVN!.34:Y*L>+"*16441C:9 4UT^D9I@(TX!E,/'+)Y
MRL37A9Q*XQ!\7&A-"R\%G-JLP_/W[A]6.)F6/N_ I\5,:(H4>.)UT>P(%C8R
M9RJ3*3W UZF LX,"X5-$M\4(%Q-*HS;#K@'V/7:(XX8\DP;A\1OHHP9)<E;D
M(FJW%N H7<Q)%8Z*O?I: G>1F,D4BP$$;+<1D^@"7L15XC(1/(5 .9OC*O4
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M@E&86(>F!=0KK(J5GBN1XPQ633%#68"E!M*ZK<6VJ9N->VR]CB52T#:,A/3
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M6L3-5#JYPRZ?F$7<994GN^L\8X)!R=+KFHW?VJ,VCHD BE"G@C</;I!*B.N
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M4>.22/!M'6'<*M#J//#:.@1&V,Q2ZD]#_:D0<X!3S'4RK1.\VUZ"WWLFT&#
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M,C4Q,#(T+GAS9%!+ 0(4 Q0    ( '5$6UL@^]8D_0H  '^&   4
M      "  5D#  !S;',M,C R-3$P,C1?;&%B+GAM;%!+ 0(4 Q0    ( '5$
M6UO>,W"-7P<  .=7   4              "  8@.  !S;',M,C R-3$P,C1?
M<')E+GAM;%!+ 0(4 Q0    ( '5$6UO"K Q_1!D  $^&   2
M  "  1D6  !T;3(U,CDU,#5D,5\X:RYH=&U02P$"% ,4    " !U1%M;R>W3
M ^<K  #IT   %@              @ &-+P  =&TR-3(Y-3 U9#%?97@Q,"TQ
M+FAT;5!+ 0(4 Q0    ( '5$6UO<K.YRJ$,   ]O 0 5              "
M :A;  !T;3(U,CDU,#5D,5]E>#0M,2YH=&U02P$"% ,4    " !U1%M;&6K(
MP_X*   &+   %0              @ &#GP  =&TR-3(Y-3 U9#%?97@U+3$N
M:'1M4$L! A0#%     @ =41;6Y"]!"\[#   >2P  !8              ( !
MM*H  '1M,C4R.34P-60Q7V5X.3DM,2YH=&U02P4&      @ "  0 @  ([<
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>tm2529505d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sls-20251024.xsd" xlink:type="simple"/>
    <context id="AsOf2025-10-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2025-10-24</startDate>
            <endDate>2025-10-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-10-24" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-10-24" id="Fact000004">0001390478</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-10-24" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-10-24" id="Fact000010">2025-10-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-10-24" id="Fact000011">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-10-24" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-10-24" id="Fact000013">001-33958</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-10-24" id="Fact000014">20-8099512</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-10-24" id="Fact000015">7 Times Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-10-24" id="Fact000016">Suite 2503</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-10-24" id="Fact000017">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-10-24" id="Fact000018">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-10-24" id="Fact000019">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-10-24" id="Fact000020">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-10-24" id="Fact000021">200-5278</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-10-24" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-10-24" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-10-24" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-10-24" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-10-24" id="Fact000026">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-10-24" id="Fact000027">SLS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-10-24" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-10-24" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
